Exelixis begins phase 3 trial of cabozantinib in metastatic renal cell ... pharmabiz.com Exelixis, Inc, a biotechnology company committed to developing small molecule therapies for the treatment of cancer, has initiated METEOR, a phase 3 pivotal trial comparing cabozantinib to everolimus in patients with metastatic renal cell carcinoma ... |
